These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33858731)

  • 1. Tyrosinemia type 1 in pediatric nephrology: Not always straightforward.
    Brito Dos Santos S; Bertholet-Thomas A; Butin M; Dubourg L; Fouilhoux A; Bacchetta J
    Arch Pediatr; 2021 May; 28(4):338-341. PubMed ID: 33858731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH).
    Rothenbuhler A; Schnabel D; Högler W; Linglart A
    Metabolism; 2020 Feb; 103S():153892. PubMed ID: 30928313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
    Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
    Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
    Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
    J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burosumab for Pediatric X-Linked Hypophosphatemia.
    Imel EA
    Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carnitine-deficient myopathy as a presentation of tyrosinemia type I.
    Nissenkorn A; Korman SH; Vardi O; Levine A; Katzir Z; Ballin A; Lerman-Sagie T
    J Child Neurol; 2001 Sep; 16(9):642-4. PubMed ID: 11575602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fanconi-Bickel syndrome and autosomal recessive proximal tubulopathy with hypercalciuria (ARPTH) are allelic variants caused by GLUT2 mutations.
    Mannstadt M; Magen D; Segawa H; Stanley T; Sharma A; Sasaki S; Bergwitz C; Mounien L; Boepple P; Thorens B; Zelikovic I; Jüppner H
    J Clin Endocrinol Metab; 2012 Oct; 97(10):E1978-86. PubMed ID: 22865906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives.
    Raimann A; Mindler GT; Kocijan R; Bekes K; Zwerina J; Haeusler G; Ganger R
    Wien Med Wochenschr; 2020 Apr; 170(5-6):116-123. PubMed ID: 31993875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panel Discussion: Some Aspects of the Management of Patients with X-Linked Hypophosphataemic Rickets.
    Torregrosa JV; Sánchez Del Pozo J; Luiz Yanes MI; Muñoz Torres M
    Adv Ther; 2020 May; 37(Suppl 2):121-126. PubMed ID: 32236878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children.
    Schindeler A; Biggin A; Munns CF
    Front Endocrinol (Lausanne); 2020; 11():338. PubMed ID: 32547492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD.
    Perwad F; Portale AA
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1097-1099. PubMed ID: 31171590
    [No Abstract]   [Full Text] [Related]  

  • 14. Congenital Conditions of Hypophosphatemia Expressed in Adults.
    Marcucci G; Brandi ML
    Calcif Tissue Int; 2021 Jan; 108(1):91-103. PubMed ID: 32409880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of patients with X-linked hypophosphatemic rickets during Covid-19 pandemic lockdown.
    Baroncelli GI; Bertelloni S; Cosci O Di Coscio M; Tyutyusheva N; D'Elios S; Peroni D
    J Pediatr Endocrinol Metab; 2021 Jul; 34(7):905-910. PubMed ID: 33887813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
    Imel EA; Glorieux FH; Whyte MP; Munns CF; Ward LM; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Mao M; Chen CY; Skrinar A; San Martin J; Portale AA
    Lancet; 2019 Jun; 393(10189):2416-2427. PubMed ID: 31104833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X-linked hypophosphatemic rickets: an Italian experts' opinion survey.
    Emma F; Cappa M; Antoniazzi F; Bianchi ML; Chiodini I; Eller Vainicher C; Di Iorgi N; Maghnie M; Cassio A; Balsamo A; Baronio F; de Sanctis L; Tessaris D; Baroncelli GI; Mora S; Brandi ML; Weber G; D'Ausilio A; Lanati EP
    Ital J Pediatr; 2019 May; 45(1):67. PubMed ID: 31151476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab.
    Sandy JL; Simm PJ; Biggin A; Rodda CP; Wall CL; Siafarikas A; Munns CF
    J Paediatr Child Health; 2022 May; 58(5):762-768. PubMed ID: 35426466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
    Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
    J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.